Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | TEK | Q02763 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 7/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829988 | 0.86 | BRAF (0.49) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3825709 | 0.85 | KDR (0.55) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL13897820 | 0.82 | KDR (0.49) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3823782 | 0.82 | KDR (0.59) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3826844 | 0.80 | KDR (0.47) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3829881 | 0.79 | BRAF (0.57) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3821579 | 0.78 | KDR (0.51) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3822495 | 0.77 | BRAF (0.49) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3829784 | 0.77 | BRAF (0.47) | KDRTEKBRAFMAPK14LCK | |
| SCHEMBL3826996 | 0.77 | KDR (0.49) | KDRTEKBRAFMAPK14LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | claimed |
| EP-1981870-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092531-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-08-16 | — | — | WO | claimed |
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | disclosed |
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | disclosed |
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | disclosed |
| WO-2007092531-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SRC, BMX, FYN | KDR 95/4885TEK 375/4885BRAF 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.